Background: We determined the response rate to MiCMA (mitoxantrone, carboplatinum, methylprednisolone and aracytin) in a group of 29 patients with Hodgkin's disease (HD) and poor prognostic factors either resistant to first line or relapsing after conventional chemotherapy and subsequently evaluated the role of autologous stem-cell transplantation (ASCT) in these patients after MiCMA.
Introduction
Most patients with Hodgkin's disease (HD) can be cured with only a primary treatment such as MOPP and ABVD. Unfortunately, 30%-40% of patients are either refractory or relapse after first-line chemotherapy. After the initial relapse, response rates to subsequent therapy vary from 0%-80%, depending on prognostic factors present at the time of diagnosis or at relapse [1] . Furthermore, response rates depend on the type and duration of response attained with the initial chemotherapy [2] [3] [4] . A study of Cancer and Leukemia Group B (CALGB) has established the superiority of ABVD-based regimens over MOPP alone in the initial treatment of advanced HD [5] . Of these patients, 61% achieved a second remission, whereas only 35% of those who suffered relapse after MOPP responded to ABVD. However, other investigators have suggested that the rates of response to salvage treatment after initial chemotherapy with MOPP, ABVD or hybrid regimens are similar [2] .
Patients with refractory or relapsed HD treated with high-dose chemotherapy and hematopoietic rescue by autologous bone marrow or peripheral blood stem cell have an overall failure-free survival of 30%-40% at two years [6] [7] [8] . However, the clinical characteristics of these patients have been very heterogeneous, making it difficult to define which patients benefit the most from such treatment. Important features include prognostic factors at diagnosis, the type of conditioning regimen used and possibly the cytoreductive or debulking regimen used before the ASCT. In this study, we treated patients with refractory or relapsed high-risk HD, who were potentially candidates for ASCT, with a novel combination called MiCMA [9] . The selection of this regimen was based on previous results in non-Hodgkin's lymphoma and on the recent data suggesting that platinumcontaining protocols are an active treatment in relapsing or resistant HD previously treated both with alkylating agents and doxorubicin [10, 11] . Our aims were to determine the response rate to this new regimen of selected poor prognosis patients with HD, minimizing the toxicity, and to evaluate the efficacy of subsequent intensedose consolidating ASCT. 
Patients and methods
Twenty-nine patients with refractory or relapsed HD were treated with MiCMA (mitoxantrone 10 mg/m 2 day 1; carboplatinum 100 mg/m 2 days \-^; aracytin 2 g/m 2 day 5; methylpredmsolone 500 mg/m 2 days 1-5). To be enrolled in this study patients had to be more than 17 and less than 60 years old, have a performance status ^ 2 by Zubrod's scale, and meet the following criteria: proven relapsed HD after prior chemotherapy with either or both MOPP and ABVD, or other comparable regimens, measurable tumor masses; adequate hematopoiesis, defined as granulocytes > 1500/ul, platelet count 3* 100,000/|il; adequate renal function, defined as creatinine $ 1.5 mg/dl; adequate liver function, defined as bilirubin ^ 1.5 mg/dl, serum glutamic pyruvic transaminase (SGPT) < 4 x upper normal limit; adequate pulmonary function, defined as forced vital capacity (FVC) > 70% and diffusion capacity of carbon monoxide (DLCO) > 50% unless abnormal due to HD in the lungs; and cardiac left ventricular ejection fraction ^ 50%. Patients were required to have had no chemotherapy or radiation therapy for three weeks before start of treatment. The study was approved by the local ethical committee and informed consent was obtained from each patient or patient's guardian.
Evaluation
Before therapy, all patients underwent a complete history and physical examination, including evaluation of performance status, presence of constitutional symptoms, and concurrent nonmalignant disease and its therapy. Prognostic factors were evaluated on the basis of response to first-line chemotherapy, duration of response, presence of extranodal involvement, presence of B symptoms at diagnosis or at relapse. Prognostic score according to Hasenclever [12] was generated from 0 to 4 at diagnosis.
Laboratory studies included a complete blood count (CBC), platelet, differential, SMA-12 (glucose, blood urea nitrogen, uric acid, calcium, phosphorus, total protein, albumin, creatinine, total bilirubin, alkaline phosphatase, serum glutamic pyruvic transaminase, and LDH), prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, urinalysis, and electrolytes. Appropriate radiological examinations for measurement or evaluation of disease were done not more than four weeks prior to the start of treatment. Further tests included bilateral bone marrow biopsy and aspiration, spirometry, electrocardiogram, echocardiogram, cytomegalovirus (CMV) titer, herpes simplex serology, human immunodeficency virus (HIV) antibody, and serologies for hepatitis A, B, and C, and Epstein-Barr virus (EBV) antibody.
After the second or third course of MiCMA, peripheral blood stem cells were harvested using G-CSF 5 ug/kg/day from day +8 from the start of cycle until completion of stem-cell harvest.
Complete response was defined as complete disappearance by physical exam and radiographic studies of all measurable or evaluable disease with no indication of recurrence before the high-dose chemotherapy consolidation. Partial response was defined as > 50%, but < 100% improvement in all measurable or evaluable disease, with no indication of tumor regrowth before high-dose chemotherapy consolidation.
Treatment plan
Patients received MiCMA chemotherapy, consisting of mitoxantrone 10 mg/m 2 /d on day 1, carboplatinum 100 mg/m 2 on days 1-4, cytosine arabinoside 2 g/m 2 on day 5 and methylprednisolone 500 mg/m 2 /d on days 1-5. After two cycles of chemotherapy, patients underwent evaluation for response with any radiographic studies pertinent to measurable or evaluable disease. The patients that showed a response of more than 80% were immediately submitted to ASCT, the patients with PR or PD were submitted to one or two further courses of MiCMA before high-dose chemotherapy and ASCT.
ASCT Twenty-nine patients were submitted to ASCT after the following conditioning regimen: twenty BEAM, seven BuCy2, one Bumel, one CVB and subsequently received PBSC previously collected after MiCMA salvage chemotherapy. Nineteen patients received unselected PBSC and ten patients were submitted to selected CD34+ PBSCT (7 with Ceprate SC and 3 with CliniMACS devices).
Statistical methods
Overall survival was measured from the time of registration on study. Curves were constructed using the method of Kaplan and Meier [13] . Differences in survival between groups according to the different covariates were analyzed by the generalized log-rank test [14] . The significance of differences in the CR rates according to various features was calculated by chi-square testing [15] .
Results
The patients had a median age of 28.8 years (range 18-46) and the group had a balanced ratio of males and females ( Table 1 ). The clinical features of the group were generally unfavorable with a predominance of stage IV at diagnosis (17 patients) and high risk II (5 patients) and III (7 patients) stages. The majority of patients had extensive disease at relapse, and 22 patients (79%) had B symptoms at diagnosis. Eleven patients (38%) had received more than one chemotherapy regimen before MiCMA, and most had received both doxorubicin and alkylating agents. After first-line chemotherapy 13 patients achieved CR with a median duration of response of 15 months (range 5-48), 14 patients showed partial response and 2 were resistant (< PR) to conventional treatment.
Response to MiCMA andASCT
Ten patients (34%) achieved CR and fifteen patients (52 %) achieved partial response (PR), for a total response rate of 86%. Three patients who showed PR after firstline chemotherapy, achieved CR after MiCMA protocol and one patient resistant to prior chemotherapy achieved CR after MiCMA. Four patients were unresponsive to MiCMA showing PD (14%). The following factors were analyzed for predicting response to MiCMA: extranodal sites, response duration to last treatment (<6 and >6 months, <12 and >12 months), B symptoms, prior radiotherapy on involved field and prognostic score from 0-4 [12] .
Twenty nine patients were submitted to ASCT. After ASCT 17 patients achieved CR (58.6%). In fact eight patients who showed partial response after salvage chemotherapy with MiCMA, achieved CR after ASCT. At the time of analysis, 13 patients are alive in CR, 6 patients are alive with HD, 1 patient is alive with histologically proven NHL at relapse, 1 patient is lost to follow-up after relapse, 8 patients died. One patient received a second ASCT for HD relapse twenty months after first ASCT and is currently alive with no evidence of HD fifty months after the second ASCT.
Toxicity
There were no deaths due to toxicity of MiCMA and no grade 3 or 4 non-hematologic toxicities. None of the patients suffered cardiac or renal toxicity. All patients developed grade 3 or 4 neutropenia, which was reversible, and grade 2-3 thrombocytopenia, also reversible. 
Overall survival analysis
At the time of this analysis, 20 of 29 (69%) patients are alive. Of the eight deaths, seven were due to HD and one to multi-organ failure at day +20 after ASCT. At four years the overall survival was 55% and the event-free survival was 33% (Figures 1 and 2) . The response to MiCMA correlated with the long-term probability of surviving the disease, although survival in this patient population is the result of the total treatment ( Figure 3) . The mortality rate due to causes other than disease was 3.4%. Only the presence of extranodal sites was associated with a worse outcome {P = 0.007). The other factors analyzed lacked statistical significance mainly due to the small number in this series and the selection of patients at high risk.
Discussion
The progress made in the treatment of Hodgkin's disease (HD) during the last 20 years offers the chance to cure the majority of patients affected by this disease. However, with current up-front therapeutic strategies, MOPP and/or ABVD, 20%-40% of patients either fail to reach a CR or relapse after primary treatment. Recently some reports showed that protocols of chemotherapy containing platinum and ara-C, were able to rescue some patients with HD either relapsed or refractory, previously treated with standard chemotherapy [10] [11] [12] [13] [14] [15] [16] . Velasquez et al. [10] reported a response rate of 87%, with 56% CR in 16 patients either relapsed or with refractory HD, treated with 6 cycles of ASHAP. In another report Rodriguez et al. [11] treated 56 patients with 2 or 3 cycles of ASHAP, followed, in responsive patients, by ASCT. In this study the response rate was of 70%, with 34% of CR and 36% of PR. All patients unresponsive to salvage chemotherapy were removed from this study. Finally the study by Rapoport et al. [17] shows a response rate of 47% in 19 patients with relapsing HD treated with DHAP before ASCT. We treated 29 patients with primary refractory or relapsed HD with a platinum-containing protocol followed by ASCT as consolidation. The majority of our patients (93%) were previously treated with anthracycline-containing regimens. Disease response was evaluated after only two cycles of MiCMA in order to debulk disease minimizing toxicity, anticipating further treatment with ASCT. The overall response rate was 86% confirming the efficacy of this regimen and a good safety profile. ASCT has been tested extensively in patients with poor prognosis HD in recent years. Most of these reports have demonstrated that 20%-30% of patients with primary refractory disease may achieve long-term disease-free survival after high-dose therapy. Sweetenham et al. [18] reported a retrospective multicenter analysis of 175 patients with HD, submitted to ASCT, who did not achieve remission after induction therapy. In this study responses to high-dose therapy and ASCT were: CR 30%, PR 28%, no response and PD in 14% and 14%, respectively, the rate of toxic death was of 14%. Baker et al. [19] treated 53 children and adolescents with relapsed or refractory HD with high-dose chemotherapy and ASCT. Results of this study showed that at day +100 post-transplant 55% of patients were in CR, 11% in PR, 11% refractory or in PD; at five years the FFS was 31% and OS was 43%. In this series nine patients died of transplantation-related complications, including two secondary leukemias. Nevertheless, in this study the role of a specific regimen of salvage chemotherapy before the ASCT was not evaluated. In our study 59% of patients achieved CR after ASCT: in fact a group of eight patients (28%) that showed PR after MiCMA protocol, achieved CR after ASCT. This result confirms the efficacy of ASCT also in patients with low chemosensitivity to standard doses of chemotherapy. At four years the OS was 55% and EFS was 33%. This observation is in agreement with the recent data from the ABMTR [20] demonstrating that some patients with HD failing primary induction therapy can attain longterm OS and progression-free survival with an ASCT. Only the presence of extranodal sites, in our series, was associated with a worse outcome, as reported by other authors [8, [21] [22] [23] . The others factors analyzed lacked statistical significance mainly due to the small number of this series and the selection of patients at high risk with a variety of poor prognostic factors.
In conclusion, our study shows that MiCMA is an effective cytoreductive treatment in patients with refractory or relapsing HD before ASCT. It was beneficial in a group of patients who had predominantly received prior anthracycline-containing chemotherapy, often with low chemosensitivity. Toxicity was negligible and the combination of drugs allowed mobilization of stem cell transplantation in all patients previously exposed to alkylating agents.
